Evaluation of the effectiveness of personalised therapy for the patients with irritable bowel syndrome

Abstract

Intestinal microbiota correction in the therapy of irritable bowel syndrome (IBS) is an important medical problem. We conducted a laboratory and pilot clinical trial to investigate the effect of autoprobiotic bacteria, indigenous bifidobacteria and enterococci isolated from faeces and grown on artificial media to use as personified food additives in IBS treatment. Convincing evidence of the clinical efficacy of autoprobiotic was demonstrated by the disappearance of dyspeptic symptoms. The microbiome of patients with IBS was compared to a group of healthy volunteers and changes in the microbiome after autoprobiotic use were detected by quantitative polymerase chain reaction and 16S rRNA metagenome analysis. The possibility of reducing opportunistic microorganisms in the treatment of IBS with autoprobiotics has been convincingly proven. The quantitative content of enterococci in the intestinal microbiota was higher in IBS patients than in healthy volunteers and increased after therapy. An increase in the relative abundance of genera Coprococcus, Blautia and a decrease in the relative abundance of Paraprevotella spp. were found at the end of therapy. A metabolome study which was performed by gas chromatography and mass spectrometry demonstrated an increase in the content of oxalic acid, a decrease of dodecanoate, lauric acid, and other metabolome components after taking autoprobiotics. Some of these parameters correlated with the relative abundances of Paraprevotella spp., Enterococcus spp., and Coprococcus spp. representative of the microbiome. Apparently, they reflected the peculiarities of metabolic compensation and changes in the microbiota. Therefore, the use of autoprobiotics for treatment of IBS may lead to a stable positive clinical effect, associated with compensatory changes in the intestinal microbiota, and accompanied by corresponding changes in metabolic processes in the organism.

Autoprobiotics in the Treatment of Patients with Colorectal Cancer in the Early Postoperative Period

“…The same model shows a beneficial effect of autoprobiotics on intestinal motility [70]. Also, we demonstrated that autoprobiotic intake contributes to a decrease in dyspeptic symptoms and is associated with positive changes in the gut microbiota content [71,72], as well as the vaginal microbiota content [73].…”

Origin and consequences of intestinal dysfunction following cytostatic chemotherapy and hematopoietic stem cell transplantation

“…Promising results are obtained with clinical isolates of autologous probiotic microorganisms, e.g., non-toxigenic enterococci from the patients' microbiota, aiming for treatment of intestinal bowel syndromes, both in experiment and in clinical settings. These data are also reviewed elsewhere in literature [34].…”